What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Alessandro Armuzzi, Alfredo Papa, Luisa Guidi, Gianluca Andrisani, Manuela Marzo, Carla Felice, Daniela Pugliese

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

The use of biological agents and immunomodulators for inflammatory bowel disease (IBD) is associated with an increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review
Lingua originaleEnglish
pagine (da-a)387-396
Numero di pagine10
RivistaWORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS
Volume7
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Anti-tumor necrosis factor agents
  • Corticosteroids
  • Immunomodulators
  • Inflammatory bowel disease
  • Opportunistic infections

Fingerprint Entra nei temi di ricerca di 'What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?'. Insieme formano una fingerprint unica.

Cita questo